NCT00629213View on ClinicalTrials.gov

Metabolic Syndrome Risk Factor in IGT: STOP-NIDDM Trial

PHASE3CompletedINTERVENTIONAL

Enrollment

1,429

Participants

Timeline

Start Date

Not specified

Conditions

Metabolic Syndrome

Interventions

DRUG

acarbose

DRUG

placebo

Trial Locations (1)

01187

GWT-TUD GmbH, Dresden

All Listed Sponsors

lead

GWT-TUD GmbH

OTHER

NCT00629213 - Metabolic Syndrome Risk Factor in IGT: STOP-NIDDM Trial | Biotech Hunter | Biotech Hunter